Marea Therapeutics
Cardiometabolic Therapeutics
4open roles
$295kmedian advertised pay
18stories in the press
10technologies in use
Overview
Marea Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies for genetically validated cardioendocrine disease targets, with a lead program called MAR001. It hires clinical trial, regulatory, data management and biostatistics leaders. The company is headquartered in South San Francisco, California, United States.
Jobs
$250k – $300k per year · In office · 15+ years exp · Bachelor's Degree · South San Francisco
GCP
Life Sciences
CDISC
Medidata Rave
Apply
$180k – $195k per year · In office · 8+ years exp · Bachelor's Degree · South San Francisco
Apply
$260k – $295k per year · In office · Full-Time · 15+ years exp · Bachelor's Degree · South San Francisco
GMP
MedTech
Design Controls
Apply
$180k – $220k per year · In office · 6+ years exp · South San Francisco
GCP
Life Sciences
Good Clinical Practice
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$295k
Typical range
$195k – $300k
Open positions
5
5
Jobs
Senior
80%
Architect
20%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 4 | $258k | $195k – $300k |
| Architect | 1 | $300k | $300k |
Highest paying role
Director, Biostatistics
$300k
Normalized to USD per year
All salaries at Marea Therapeutics
By role, level and city, against the market · 5 jobs with pay
Visa sponsorship
1
H-1B filings in 12 months
$138k
Median offered salary
5
Open roles in United States
Who they sponsor
Other biological scientists
1
In the register as Marea Therapeutics Inc., South San Francisco, CA
Other sponsors in the same field
Eli Lilly and Company 420 filings
Amgen 372 filings
Bristol Myers Squibb 218 filings
Novo Nordisk 39 filings
See 5 open roles Alert me
US Department of Labor · latest filing Nov 24, 2025 · Visa details by country
Growth
Hiring Momentum
25/100
Slowing
Open positions
5
0 opened / 0 closed in 30 days
Median time-to-fill
42 days
faster than 32% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
33% ▲
Leadership
17% ▼
Finance
17% ▼
Industrial Engineering
17% ▼
Early Careers
17% ▼
Tech stack
Technologies named in job postings at Marea Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
10
Postings analysed
6
Stack modernity
53/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Full Marea Therapeutics tech stack
10 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Show all 4 
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by
Read more
Report
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by
Read more
Report
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function South San Francisco, CA and Liberty Corner, N.J., September 2
Read more
Report
Marea Corporate Presentation
The post Marea Corporate Presentation appeared first on Marea Therapeutics.
Read more
Report
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002...
Read more
Report
San Francisco Business Times Best Places to Work 2026
The post San Francisco Business Times Best Places to Work 2026 appeared first on Marea Therapeutics.
Read more
Report
Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026
Read more
Report
Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026
MAR002 demonstrates deep and durable IGF-1 suppression up to 64% with favorable PK properties potentially enabling once every two-week dosing Phase 2/3 study of MAR002 in acromegaly to initiate in mid-2026 South San Francisco, Calif., June 15, 2026 - Mare
Read more
Report
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026
South San Francisco, Calif., May 26, 2026 - Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announce
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
South San Francisco
South San Francisco
United States
HQ
South San Francisco
5 open roles 6 posted in 90 days $262k Avg Salary
hires for Biotech, Leadership, Early Careers
131 Oyster Point Boulevard, Floor 4, South San Francisco, CA 94080